Download Literaturliste Prostata-Ca - Philipps

Referenzen zu:
DGU, EAU, AUA, ASCO 2007: Relevantes und Innovatives für die
Urologische Onkologie in Klinik und Praxis
UPDATE PRPOSTATAKARZINOM
P. J. Olbert
Klinik für Urologie und Kinderurologie, Philipps-Universität Marburg,
Baldingerstrasse, D-35043 Marburg
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Ulmert D et al. Value of PSA measured in middle age in predicting diagnosis of
advanced prostate cancer in an unscreened population. J Clin Oncol 25, 18S
(2007): 236S Abstract 5006
Rettig BM et al. Evaluation of pomegranate polyphenol – mediated suppression of
nuclear factor kappa B activity in prostate cancer cell lines. J Urol 177, 4 Suppl.
(2007): 46 Abstract 137
Srivastava JK et al. Tocorienol-rich fraction of palm oil leads to growth inhibition
and apoptosis of PC-3 tumor xenografts in athymic nude mice. J Urol 177, 4
Suppl. (2007): 46 Abstract 138
Venkatesvaran V et al. Early commencement of micronutrients is beneficial in
reducing the incidence of prostate cancer. J Urol 177, 4 Suppl. (2007): 47 Abstract
139
van Oort IM et al. The 2002 TNM subclassification of unilateral pT2 prostate
cancer is not relevant. J Urol 177, 4 Suppl. (2007): 112 Abstract 331
Cohen MS et al. A meta-analysis evaluating the accuracy of prostate Gleason
biopsy in over 11.000 patients. J Urol 177, 4 Suppl. (2007): 249 Abstract 743
Jeldres C et al. The role of digital rectal examitation in prediction of pathological
stage after radical prostatectomy in contemporary patients. J Urol 177, 4 Suppl.
(2007): 337 Abstract 1023
Bolla M et al. Concomitant and adjuvant androgen deprivation (ADT) with
external beam irradiation for locally advanced prostate cancer: 6 months versus 3
years ADT – results of the randomized EORTC phase III trial 22961. J Clin Oncol
25, 18S (2007): 238S Abstract 5014
Souhami L et al. The impact of the duration of adjuvant hormonal therapy in
patients with unfavourable prognosis prostate cancer treated with radiotherapy:
secondary results of RTOG 85-31. J Clin Oncol 25, 18S (2007): 250S Abstract
5062
Association of cerebrovascular accident and myocardial infarction with androgen
deprivation therapy. Malcolm JB et al. J Urol 177, 4 Suppl. (2007): 200 Abstract
597
Increased risk of newly diagnosed comorbidities in porstate cancer patients treated
with androgen deprivation therapy. J Urol 177, 4 Suppl. (2007): 200 Abstract 598
Tsai HK et al. Androgen deprivation therapy for prostate cancer and the risk of
cardiac mortality. J Urol 177, 4 Suppl. (2007): 124 Abstract 378
Touijer K et al. Comprehensive, prospective, comparative analysis of outcomes
between open and laparoscopic radical prostatectomy. J Urol 177, 4 Suppl. (2007):
184 Abstract 553
14.
15.
16.
17.
18.
19.
20.
21.
Tunn U et al. Intermittent androgen deprivation in patients with PSA-relapse after
radical prostatectomy. Final results of a European, randomized prospective phase
III clinical trial. J Urol 177, 4 Suppl. (2007): 201 Abstract 600
Briganti A et al. Excellent long term outcome of patients with low volume of
lymph node invasion treated with extended pelvic lymph node dissection at the
time of radical prostatectomy. J Urol 177, 4 Suppl. (2007): 243 Abstract 724
Freedland SJ et al. Radical prostatectomy for clinical stage T3 disease. J Urol 177,
4 Suppl. (2007): 243 Abstract 725
Berthold DR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer: updated survival of the TAX 327 study. J Clin Oncol 25,
18S (2007): 236S Abstract 5005
Armstrong AJ et al. Analysis of prostate specific antigen decline as a surrogate for
overall survival in metastatic hormone refractory prostate cancer (HRPCA). J Clin
Oncol 25, 18S (2007): 237S Abstract 5009
Miller K et al. Randomized prospective study of intermittent versus continuous
androgen suppression in advanced prostate cancer. J Clin Oncol 25, 18S (2007):
238S Abstract 5015
Satraplatin (S) demonstrates significant clinical benefits for the treatment of
patients with HRPC: Results of a randomised phase III trial. J Clin Oncol 25, 18S
(2007): 239S Abstract 5019
Machiels JH et al. Phase III trial of docetaxel (D), estramustine (E) and prednisone
versus docetaxel plus prednisone in patients with metastatic hormone refractory
prostate cancer (HRPC). J Clin Oncol 25, 18S (2007): 250S Abstract 5067